Drug intelligence / Profile preview

RK019

Development stage: Preclinical
Lead developer: RevolKa
Modality: Recombinant Proteins and Enzymes
Administration: Oral, Intravenous

Overview

RK019 is a protein-based therapeutic candidate being developed by RevolKa for the treatment of rare diseases. The drug was discovered and optimized using RevolKa's proprietary "evolve" platform, which utilizes directed evolution and high-throughput screening to enhance protein functions. RK019 is currently in the research and development phase, with its specific molecular target and the exact rare disease indication remaining undisclosed by the company.

Targets

FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)VEGFR4 (Vascular endothelial growth factor Receptor-3)LYN (LYN proto-oncogene, Src family tyrosine kinase)RET (Rearranged during transfection receptor tyrosine kinase)

Beyond the preview

Go deeper on RK019.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RK019.